References
- Stupp R , HegiME, MasonWPet al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomized Phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol.10(5), 459–466 (2009).
- Grossman SA , YeX, PiantadosiSet al. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin. Cancer Res.16(8), 2443–2449 (2010).
- Jackson M , HassiotouF, NowakA. Glioblastoma stem-like cells: at the root of tumor recurrence and a therapeutic target. Carcinogenesis36(2), 177–185 (2015).
- Jhanwar-Uniyal M , LabagnaraM, FriedmanM, KwasnickiA, MuraliR. Glioblastoma: molecular pathways, stem cells and therapeutic targets. Cancers (Basel)7(2), 538–555 (2015).
- Stupp R , MasonWP, van den BentMJet al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med.352(10), 987–996 (2005).
- Weller M , GorliaT, CairncrossJGet al. Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology77(12), 1156–1164 (2011).
- Sardi I , la MarcaG, CardellicchioSet al. Pharmacological modulation of blood–brain barrier increases permeability of doxorubicin into the rat brain. Am. J. Cancer Res.3(4), 424–432 (2013).
- Lesniak MS , UpadhyayU, GoodwinR, TylerB, BremH. Local delivery of doxorubicin for the treatment of malignant brain tumors in rats. Anticancer Res.25(6B), 3825–3831 (2005).
- Veringa SJ , BiesmansD, van VuurdenDGet al. In vitro drug response and efflux transporters associated with drug resistance in pediatric high grade glioma and diffuse intrinsic pontine glioma. PLoS ONE8(4), e61512 (2013).
- Giunti L , da RosM, VinciSet al. Anti-miR21 oligonucleotide enhances chemosensitivity of T98G cell line to doxorubicin by inducing apoptosis. Am. J. Cancer Res.5(1), 231–242 (2014).
- Singh SK , HawkinsC, ClarkeIDet al. Identification of human brain tumour initiating cells. Nature432(7015), 396–401 (2004).
- Eramo A , Ricci-VitianiL, ZeunerAet al. Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ.13(7), 1238–1241 (2006).
- Chiang CS , McBrideWH, WithersHR. Radiation-induced astrocytic and microglial responses in mouse brain. Radiother. Oncol.29(1), 60–68 (1993).
- Monje ML , PalmerT. Radiation injury and neurogenesis. Curr. Opin. Neurol.16(2), 129–134 (2003).
- Qin DX , ZhengR, TangJ, LiJX, HuYH. Influence of radiation on the blood–brain barrier and optimum time of chemotherapy. Int. J. Radiat. Oncol. Biol. Phys.19(6), 1507–1510 (1990).
- van Vulpen M , KalHB, TaphoornMJ, El-SharouniSY. Changes in blood–brain barrier permeability induced by radiotherapy: implications for timing of chemotherapy?Oncol. Rep.9(4), 683–688 (2002).
- Cicciarello R , d’AvellaD, GagliardiMEet al. Time-related ultrastructural changes in an experimental model of whole brain irradiation. Neurosurgery38(4), 772–779 (1996).
- Yuan H , GaberMW, BoydK, WilsonCM, KianiMF, MerchantTE. Effects of fractionated radiation on the brain vasculature in a murine model: blood–brain barrier permeability, astrocyte proliferation, and ultrastructural changes. Int. J. Radiat. Oncol. Biol. Phys.66(3), 860–866 (2006).
- van Dalen EC , van de PalHJ, CaronHN, KremerLC. Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy. Cochrane Database Syst. Rev.4, CD005008 (2009).